Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

NCT01281098 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

High Risk Proliferative Diabetic Retinopathy
Diabetes Mellitus Type I
Diabetes Mellitus Type II

Interventions

PROCEDURE: Panretinal Photocoagulation (PRP)
DRUG: Intravitreous injection of pegaptanib

Sponsor

Association for Innovation and Biomedical Research on Light and Image